Use of beta-adrenergic blocking agents after myocardial infarction

References

• May GS, Furberg CD, Eberlein KA, et al. Secondary prevention trials after myocardial infarction: a review of short-term acute phase trials. Prog Cardio-vasc Dis 1983: 25(4): 335–59
   PubMed Web of Science ®Google Scholar
• May GS, Eberlein KA, Furberg CD, et al. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 1982: 24(4): 331–52
   PubMed Web of Science ®Google Scholar
• Pearle DL. Nifedipine in acute myocardial infarction. Am J Cardiol 1984: 54(11): 21–3E
   Google Scholar
• Danish Multicenter Study Group. Verapamil in acute myocardial infarction. Am J Cardiol 1984: 54(1): 24–8E
   Google Scholar
• Turi ZG, Braunwald E. The use of beta-blockers after myocardial infarction. JAMA 1983: 249(18): 2512–6
   PubMed Web of Science ®Google Scholar
• Frishman WH, Furberg CD, Friedewald WT. Beta- adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984: 310(13): 830–7
   PubMed Web of Science ®Google Scholar
• Frishman WH, Furberg CD, Friedewald WT. The use of beta-adrenergic blocking drugs in patients with myocardial infarction. Curr Prob Cardiol 1984: 9(3): 1–50
   PubMedGoogle Scholar
• Frishman WH. Clinical pharmacology of the beta- adrenoceptor blocking drugs. 2d ed. East Norwalk. CT: Appleton-Century-Crofts. 1984: 51
   Google Scholar
• Snow PJ. Effect of propranolol in myocardial infarction. Lancet 1965: 2(412): 551–3
   PubMedGoogle Scholar
• Balcon R, Jewitt DE, Davies JP, et al. A controlled trial of propranolol in acute myocardial infarction. Lancet 1966: 2(470): 918–20
   PubMedGoogle Scholar
• Clausen J, Felsby M, Jorgensen FS, et al. Absence of prophylactic effect of propranolol in myocardial infarction. Lancet 1966: 2(470): 920–4
   PubMedGoogle Scholar
• Multicentre Trial Study Group. Propranolol in acute myocardial infarction. Lancet 1966: 2: 1435–7
   PubMed Web of Science ®Google Scholar
• Norris RM, Caughey DE, Scott PJ. Trial of propranolol in acute myocardial Infarction. Br Med J 1968: 2(602): 398–400
   PubMedGoogle Scholar
• Wilhelmsson C, Vedin JA, Wilhelmsen L, et al. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol: preliminary results. Lancet 1974: 2(7890): 1157–60
   PubMed Web of Science ®Google Scholar
• Vedin A, Wilhelmsson C, Werko L. Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital: effects on mortality and morbidity. Acta Med Scand (Suppl) 1975: 575: 3–56
   PubMedGoogle Scholar
• Ahlmark G, Saetre H, Korsgren M. Reduction of sudden deaths after myocardial infarction. (Letter) Lancet 1974: 2(7896): 1563
   PubMed Web of Science ®Google Scholar
• Ahlmark G, Saetre H. Long-term treatment with beta-blockers after myocardial infarction. Eur J Clin Pharmacol 1976: 10(2): 77–83
   PubMed Web of Science ®Google Scholar
• Barber JM, Boyle DM, Chaturvedi NC, et al. Practolol in acute myocardial infarction. Acta Med Scand (Suppl) 1976: 587: 213–9
   PubMedGoogle Scholar
• Multicentre International Study. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. Br Med J 1975: 3: 735–40
   PubMedGoogle Scholar
• Multicentre International Study. Reduction in mortality after myocardial infarction with long-term beta-adrenoreceptor blockade: supplementary report. Br Med J 1977: 2: 419–21
   PubMedGoogle Scholar
• Andersen MP, Bechsgaard P, Frederiksen J, et al. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction: preliminary results. Lancet 1979: 2(8148): 865–8
   PubMed Web of Science ®Google Scholar
• Baber NS, Evans DW, Howitt G, et al. Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom. Italy, and Yugoslavia. Br Heart J 1980: 44(1): 96–100
   PubMedGoogle Scholar
• Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981: 304: 801–7
   PubMed Web of Science ®Google Scholar
• Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982: 247: 1707–14
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981: 2(8251): 823–7
   PubMed Web of Science ®Google Scholar
• Hansteen V, Moinichen E, Lorentsen E, et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J (Clin Res) 1982: 284(6310): 155–60
   PubMedGoogle Scholar
• Julian DG. Prescott RJ, Jackson FS, et al. A controlled trial of sotalol for one year after myocardial infarction. Lancet 1982: 1 (8282): 1142–7
   PubMed Web of Science ®Google Scholar
• Taylor SH, Silke B, Ebbutt A, et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 1982: 307(21): 1293–301
   PubMed Web of Science ®Google Scholar
• Australian and Swedish Pindolol Study Group. The effect of pindolol on the two-year mortality after complicated myocardial infarction. Eur Heart J 1983: 4: 367–75
   PubMed Web of Science ®Google Scholar
• European Infarction Study Group. European Infarction Study: a secondary beta-blocker prevention trial after myocardial infarction. (Abstr) Circulation 1983: 68(Suppl 3): III–294
   PubMedGoogle Scholar
• Cutler JA. A review of ongoing trials of beta blockers in the secondary prevention of coronary heart disease. Circulation 1983: 67(6 Pt 2): 162–5
   PubMedGoogle Scholar
• Lichstein E, Morganroth J, Harrist R, et al. Effect of propranolol on ventricular arrhythmia: the Beta-Blocker Heart Attack Trial experience—preliminary data. Circulation 1983: 67(6 Pt 2): 15–10
   Google Scholar
• Von der Lippe G, Lund-Johansen P, Kjekshus J. Effect of timolol on late ventricular arrhythmias after acute myocardial infarction. Acta Med Scand (Suppl) 1981: 651: 253–63
   PubMedGoogle Scholar
• Frishman WH. Multifactorial actions of beta- adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation 1983: 67(6 Pt 2): 111–8
   Google Scholar
• Braunwald E, Muller JE, Kloner RA, et al. Role of beta-adrenergic blockade in the therapy of patients with myocardial infarction. Am J Med 1983: 74(1): 113–23
   PubMed Web of Science ®Google Scholar
• Multicenter Postinfarction Research Group. Risk stratification after myocardial infarction. N Engl J Med 1983: 309: 331–6
   PubMed Web of Science ®Google Scholar
• Friedman LM. How do the various beta blockers compare in type, frequency and severity of their adverse effects? Circulation 1983: 67(6 Pt 2): 189–90
   Google Scholar
• Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation 1984: 69(4): 761–5
   PubMed Web of Science ®Google Scholar
• Griggs TR, Wagner GS, Gettes LS. Beta-adrenergic blocking agents after myocardial infarction: an undocumented need in patients at lowest risk. J Am Coll Cardiol 1983: 1(6): 1530–3
   PubMed Web of Science ®Google Scholar
• Furberg CD, Bell RL. Effect of beta-blocker therapy on recurrent nonfatal myocardial infarction. Circulation 1983: 67(6 Pt 2): 183–5
   PubMedGoogle Scholar
• MIAMI Trial Research Group.. Metoprolol in acute myocardial infarction (MIAMI). Eur Heart J 1985: 6: 199–226
   PubMed Web of Science ®Google Scholar
• Evemy KL, Pentecost BL. Intravenous and oral practolol in the acute stages of myocardial infarction. Eur J Cardiol 1978: 7(5–6): 391–8
   PubMedGoogle Scholar
• Johansson BW. A comparative study of cardiose-lective beta-blockade and diazepam in patients with acute myocardial infarction and tachycardia. Acta Med Scand 1980: 207(1–2): 47–53
   PubMedGoogle Scholar
• Yusuf S, Sleight P, Rossi P, et al. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 1983: 67(6 Pt 2): 132–41
   Google Scholar
• McIlmoyle L, Evans A, Boyle DM, et al. Early intervention in myocardial ischaemia. (Abstr) Br Heart J 1982: 47: 189
   Web of Science ®Google Scholar
• International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984: 310(1): 9–15
   PubMed Web of Science ®Google Scholar
• Roberts R. Croft C, Gold HK, et al. Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. N Engl J Med 1984: 311(4): 218–25
   PubMed Web of Science ®Google Scholar
• Goldstein S. Propranolol therapy in patients with acute myocardial infarction: The Beta-Blocker Heart Attack Trial. Circulation 1983: 67(6 Pt 2): 153–7
   Google Scholar
• Pedersen TR. Six-year follow-up of the Norwegian Multi-Center Study on timolol after acute myocardial infarction. N Engl J Med 1985: 313(17): 1055–8
   PubMed Web of Science ®Google Scholar
• Leren P, Foss PO, Helgeland A, et al. Effect of propranolol and prazosin on blood lipids: the Oslo study. Lancet 1980: 2(8184): 4–6
   PubMed Web of Science ®Google Scholar
• Shulman RS, Herbert PN, Capone RJ, et al. Effects of propranolol on blood lipids and lipoproteins in myocardial infarction. Circulation 1983: 67(6 Pt 2): 119–21
   Google Scholar
• Baber NS, Lewis JA. Beta-adrenoceptor blockade and myocardial infarction: when should treatment start and for how long should it continue? Circulation 1983: 67(6 Pt 2): 171–7
   PubMedGoogle Scholar
• Harrison DC. Beneficial effects of beta blockers: a class action or individual pharmacologic spectrum? Circulation 1983: 67(6 Pt 2): 177–82
   Google Scholar